ʻO ke kanaka ROS1 Fusion Gene Mutation

ʻO ROS1 kahi transmembrane tyrosine kinase o ka ʻohana insulin receptor.Ua hōʻoia ʻia ʻo ROS1 fusion gene ma ke ʻano koʻikoʻi ʻē aʻe ʻaʻole liʻiliʻi liʻiliʻi liʻiliʻi ka maʻi maʻi maʻi maʻi maʻi maʻi maʻi maʻi.Ma ke ʻano he ʻelele o kahi subtype molecular hou, ʻo ka hanana o ROS1 fusion gene ma NSCLC Ma kahi o 1% a 2% ROS1 ka nui o ka hoʻoponopono hou ʻana i kāna mau exons 32, 34, 35 a me 36. Ma hope o ka hoʻohui ʻia ʻana me nā genes e like me CD74, EZR, SLC34A2, a me SDC4, e hoʻomau ia i ka hoʻoulu ʻana i ka ʻāpana ROS1 tyrosine kinase.Hiki i ka ROS1 kinase ho'ā 'ole ke ho'āla i nā ala hōʻailona o lalo e like me RAS/MAPK/ERK, PI3K/Akt/mTOR, a me JAK3/STAT3, no laila ke komo ʻana i ka hoʻomāhuahua ʻana, ka ʻokoʻa a me ka metastasis o nā pūnaewele tumo, a me ka hoʻoulu ʻana i ka maʻi kanesa.Ma waena o ROS1 fusion mutations, CD74-ROS1 helu ma kahi o 42%, EZR ma kahi o 15%, SLC34A2 ma kahi o 12%, a me SDC4 ma kahi o 7%.Ua hōʻike ʻia nā haʻawina ʻo ka ATP-binding site o ka catalytic domain o ROS1 kinase a me ka ATP-binding site o ALK kinase he homology a hiki i ka 77%, no laila, ʻo ka ALK tyrosine kinase liʻiliʻi mole inhibitor crizotinib a pēlā aku i maopopo ka hopena curative. i ka mālama ʻana i ka NSCLC me ka fusion mutation o ROS1.No laila, ʻo ka ʻike ʻana i nā mutation fusion ROS1 ke kumu a me ke kumu no ke alakaʻi ʻana i ka hoʻohana ʻana i nā lāʻau lapaʻau crizotinib.